Anaphylactic Shock to a DEET-Containing Insect Repellent

Giangrande N1, García-Menaya J1, Vergara-Prieto E2, Pineda de la Losa F3, Castillo-Fernández M1, Cordobés-Durán C4, Marcos-Fernández M5, Bobadilla-González P6
1Allergy Department, Badajoz University Hospital, Badajoz, Spain
2Immunology Department, Cáceres University Hospital, Cáceres, Spain
3Diater Laboratories, Madrid, Spain
4Allergy Department, Don Benito General Hospital, Don Benito, Spain
5Primary Health Care Center Pueblonuevo del Guadiana, Badajoz, Spain

J Investig Allergol Clin Immunol 2021; Vol. 31(4): 336-338
doi: 10.18176/jiaci.0644

Key words: Anaphylaxis. Basophil activation test. Dot blot. DEET.

Palabras clave: Anafilaxia. Test de activación de basófilos. Dot blot. DEET.

In recent decades, increased awareness of many insect-borne diseases (eg, malaria, dengue hemorrhagic fever, and West Nile virus) has generated a rapidly growing number of insect repellents in order to prevent transmission. N,N-diethyl-3-methylbenzamide, otherwise known as N,N-diethyl-meta-toluamid, diethyltoluamide (DEET), is a reliable option [1]. DEET was originally patented in 1946 by the US Army for military use in insect-infested areas and subsequently registered in 1957 for use by the general public. The properties of DEET have led it to be considered the best protection against arthropod-borne diseases, and it is now the major active ingredient in most topical insect repellents [2].

Despite the widespread use of DEET as an insect repellent, it has caused very few cases of contact urticaria [3-7] or urticaria [8], and, to our knowledge, only 1 case of anaphylaxis caused by DEET was published in 1982 [9]. We report a case of anaphylactic shock after application of an insect repellent containing DEET in which the allergology study yielded positive results.

A 28-year-old woman with a previous history of allergic rhinoconjunctivitis and asthma and sensitization to pollens experienced tingling of the lips after indirect airborne contact with an insect repellent known commercially as Medcell (water, diethyltoluamide, ethylhexyl methoxycinnamate, ethylhexyl salicylate, methylene bis-benzotriaezolyl, tetramethylbutylphenol, mineral oil, isopropyl myristate, cetyl alcohol, glyceryl stearate/PEG-100 stearate, cetyl acetate/acetylated lanolin alcohol, isopropyl palmitate, methylparaben, fragrance of benzyl benzoate and coumarin, triethanolamine, propylparaben, carbomer). A few minutes later, the patient applied the same insect repellent on her legs. She immediately developed labial edema, dyspnea, dysphagia, generalized rash, and dizziness. Assessment in the emergency department revealed tachycardia, tachypnea,
and blood pressure of 90/40 mm Hg. She was treated with intravenous hydrocortisone (200 mg), dexamethasone (5 mg), ranitidine (50 mg), intramuscular epinephrine (0.7 mg), fluid therapy, and nebulized budesonide and salbutamol. In the absence of improvement, the patient was admitted to the critical care unit, although her condition improved within a few days. Serum tryptase was not measured during the reaction.

She was subsequently referred to our department, where an allergy study was performed 1 month after the reaction. We took a detailed history, which allowed us to rule out the simultaneous use of other drugs and the presence of possible cofactors. The allergy study was based on a high suspicion of causality for the repellent solution applied to the skin. The basal serum tryptase level was normal (2.76 µg/L).

An open patch test was performed by applying a small drop of the repellent solution on the patient’s forearm. The same test yielded negative results in 5 atopic controls. A basophil activation test (BAT) based on whole blood was performed with the repellent solution and with DEET. Both substances were tested along a dose-response curve using several dilutions. Double staining was performed with CD203c-PE to select the basophil population and CD63-FITC to measure basophil activation.

Thus, the investigation was extended using a dot blot assay. After dilution in phosphate-buffered saline (PBS), the extracts were coated on a nitrocellulose membrane using a 96-well dot-blot system. The membrane was removed from the device and blocked in PBS-Tween 20.5% for 1 hour at room temperature. The membrane was then incubated overnight with patient serum (dilution 1/5 in PBS-Tween 20.5% at 4°C). Finally, a dot blot inhibition assay was performed after preincubating the patient’s serum (diluted 1/5) for 30 minutes with different concentrations of DEET extract.

Open patch testing with a small drop of Medcell repellent led to erythema and a wheal of 6 × 3 cm within a few minutes. The CD63 BAT, which was conducted with Medcell and with DEET, yielded a positive response for both DEET and Medcell (Figure and Figure E1 in the Online Repository).

Dot blot assay was also positive for DEET and for Medcell. The recognition of the repellent solution in its entirety was greater than that of isolated DEET (Figure E2 in the Online Repository). Finally, the dot blot inhibition assay revealed total inhibition of specific IgE to the repellent with DEET (Figure E3 in the Online Repository).

Based on the clinical history and allergy study results, the patient was diagnosed with an anaphylactic reaction to DEET. We subsequently advised her to check the excipients of repellent solutions to ensure that they did not contain DEET.

Hypersensitivity reactions associated with DEET insect repellent are very unusual, with almost all cases involving contact urticaria [3-7] or urticaria [8]. To date, the only case of anaphylaxis caused by DEET was that reported by Miller [9] in 1982. A 42-year-old woman touched a companion who had just sprayed himself with an insect repellent containing DEET. She experienced generalized pruritus, generalized angioedema, and nausea and eventually lost consciousness. In the emergency room, her blood pressure was 70/40 mm Hg.

The main diagnostic tool comprises a detailed history and skin test (open patch test on the forearm) showing a causal relationship with DEET. Very few in vitro studies with DEET have been performed. Galassi et al [6] presented the first positive BAT result with DEET in a case of contact urticaria in a 50-year-old woman who had an urticarial reaction to multiple DEET-based insect repellents. She reported an urticarial rash on the exposed areas a few minutes after application of the spray, aerosol, or lotion containing DEET. Wantke et al [8] searched unsuccessfully for the presence of specific IgE to DEET using ELISA in the case of a 4-year-old boy who, shortly after applying DEET (contained in an insect repellent called Anti-Muckenmilch) to his legs and forearms, developed generalized itch and urticaria and also wheezed and coughed for 30 minutes.

In conclusion, we report a case of very severe anaphylactic reaction to DEET contained in an insect repellent solution. The condition was diagnosed based on the clinical history and a positive open patch test result, positive BAT results to DEET, and a dot blot assay. Dot blot inhibition assay also revealed total inhibition of specific IgE to the repellent with DEET. These data suggest an IgE-mediated immunological mechanism. To our knowledge, this is the first case of anaphylaxis to DEET with a positive result in an in vitro study.

**Funding**

The authors declare that no funding was received for the present study.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Previous Presentation**

This case report was partially presented as a poster at the 2019 EAACI Congress in Lisbon, Portugal.
Kounis Syndrome due to Urapidil
Herrera-Lasso V 1, Dordal MT 1, Alonso G 2, Camprubí I 2, Lleonart R1
1 Allergy Unit, Internal Medicine Department, Bellvitge University Hospital, Barcelona, Spain
2 Anesthesiology Department, Bellvitge University Hospital, Barcelona, Spain
J Investig Allergol Clin Immunol 2021; Vol. 31(4): 338-340
doi: 10.18176/jiaci.0645

Key words:
Kounis syndrome. Drug hypersensitivity. Drug allergy. Antihypertensive. Urapidil.
Palabras clave:
Síndrome de Kounis. Hipersensibilidad a medicamentos. Alergia a medicamentos. Antihipertensivo. Urapadil.

Urapidil is a sympatholytic antihypertensive drug that acts as an α1-adrenoreceptor antagonist and partial receptor agonist of serotonin. Kounis syndrome is a hypersensitivity coronary disorder involving the whole clinical spectrum of acute myocardial ischemia [1,2]. It is induced by exposure to drugs (especially antibiotics), food, and Hymenoptera venom [2,3]. We report a case of hypersensitivity to urapidil that seemed to manifest as Kounis syndrome.

The patient was a 71-year-old man with grass pollen allergy and a clinical history of obesity and paroxysmal atrial fibrillation that was well controlled with antiarrhythmic, anticoagulant, and ß-blocker therapy. He had been accepted for hip arthroplasty with normal preoperative tests.

During the initial stage of surgery, he experienced a hypertensive crisis, which was treated. Immediately after treatment, his blood pressure dropped (60/40 mmHg), and transitory inferior and lateral ST-segment elevation were registered on the electrocardiogram (ECG). His pulse recovered spontaneously after cardiopulmonary resuscitation. Transthoracic echocardiography (TTE) revealed a minor dysfunction with inferior hypokinesia. Vasoactive drug therapy was initiated, and surgery was postponed. Hypokinesia persisted after hemodynamic stabilization, and the ST segment was normalized. Cardiac catheterization disclosed no coronary lesions, and the patient was eventually diagnosed with vasospasm of the right coronary artery. Troponin T levels were 7 ng/L (normal, ≤13 ng/L).

The inpatient underwent surgery a week later, with no intraoperative adverse events. During the process of awakening, while still intubated, he experienced another hypertensive event. Urapidil was administered, with immediate onset of hypotension, ST-segment elevation in the ECG, and inferior and posterior hypokinesia in the TTE. Vasoactive drug therapy and sedation-analgesia were initiated. The troponin T level was 43 ng/L. The patient remained under surveillance in the postanesthesia care unit, with no further incidents. Tryptase levels were not measured in either reaction.

References
1. Sudakin DL, Trevathan WR. DEET: a review and update of safety and risk in the general population. J Toxicol Clin Toxicol. 2003;41:831-9.
2. Osimitz TG, Murphy JV, Fell LA, Page B. Adverse events associated with the use of insect repellents containing N,N-diethyl-m-toluamide (DEET). Regul Toxicol Pharmacol. 2010;56:93-9.
3. Maibach HI, Johnson HL. Contact urticaria syndrome. Contact urticaria to diethyltoluamide (immediate-type hypersensitivity). Arch Dermatol. 1975;111:726-30.
4. Von Mayenburg J, Rakoski J. Contact urticaria to diethyltoluamide. Contact Dermatitis. 1983;9:171.
5. Vozmediano JM, Armario J, Gonzalez-Cabrerizo A. Immunologic contact urticaria from diethyltoluamide. Int J Dermatol. 2000;39:876-7.
6. Galassi N, Romero DS, Yeyati E, Malbrán A. Diethyltoluamide (DEET) increases CD63 expression in a contact urticaria patient’s basophils. Allergol Immunopathol (Madr). 2011;39:55-7.
7. Shutty B, Swender D, Chernin L, Tcheurekdjian H, Hostoffer R. Insect repellents and contact urticaria: differential response to DEET and picaridin. Cutis. 2013;91:280-2.
8. Wantke F, Focke M, Hemmer W, Gotz M, Jarisch R. Generalized urticaria induced by a diethyltoulamide-containing insect repellent in a child. Contact Dermatitis 1996;35:186-7.
9. Miller JD. Anaphylaxis associated with insect repellent. N Engl J Med. 1982;307:1341-2.

Manuscript received June 14, 2020; accepted for publication September 14, 2020.

Jesús Miguel García-Menaya
Allergy Department
Badajoz University Hospital
Av de Elvas, s/n
06011 Badajoz, Spain
E-mail: jesusmiguelgarciamenaya@gmail.com